Bernstein Liebhard Files Class Action Against Fractyl Health
News related to:Fractyl Health, Inc · 2 min read
NEW YORK, Sept. 17, 2026 /CourierPR/ -- Bernstein Liebhard LLP has announced the filing of a securities fraud class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS). The lawsuit, brought on behalf of investors who purchased or acquired Fractyl Health, Inc. securities between January 13, 2025, and January 29, 2026, alleges that the company made materially false and misleading statements regarding its business operations, growth prospects, and financial stability. According to the lawsuit, these misrepresentations led to an artificial inflation of the company’s stock prices during the class period. When the truth was disclosed, investors suffered significant financial losses.
The lawsuit, filed on behalf of a shareholder, claims that the defendants in the case misrepresented the company’s financial health and growth potential, leading investors to make decisions based on false information. The class period is defined as all individuals who purchased or acquired Fractyl Health, Inc. securities between January 13, 2025, and January 29, 2026, inclusive.
Investors who believe they may have been affected by these alleged misrepresentations are encouraged to act promptly and submit a form at the Fractyl Health, Inc. Shareholder Class Action Lawsuit website or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or via email at [email protected]. Investors have until October 20, 2026, to file a motion to serve as lead plaintiff for the class. If no action is taken, investors may remain as absent class members.
Bernstein Liebhard LLP, a law firm with a history of recovering over $3.5 billion for its clients, has been retained to represent the interests of the class. The firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and has been listed in The Legal 500 for sixteen consecutive years. The firm has a track record of success in litigating hundreds of class action lawsuits.
The lawsuit alleges that the defendants failed to disclose material information that would have affected the stock price and misled investors about the company’s financial stability and growth prospects. The firm claims that the misrepresentations were made to artificially inflate the stock price, which subsequently dropped when the truth was revealed.
Investors who purchased Fractyl Health, Inc. securities during the class period and suffered financial losses are encouraged to contact the firm to learn more about their legal rights. The firm offers representation on a contingency fee basis, meaning that investors do not have to pay any fees or expenses unless they are successful in their claims.